Anonymousabout 10 hours ago
President Trump signed an executive order on April 2, 2026, imposing tariffs of up to 100% on imported patented pharmaceuticals under Section 232 national security authority, with reduced rates for companies that commit to building U.S. manufacturing facilities or accept "most favored nation" pricing. The order has drawn $480 billion in onshoring pledges from 14 major drugmakers but faces skepticism from economists and trade attorneys who question whether tariffs can lower consumer drug costs or meaningfully accelerate domestic production given 5-to-10-year facility timelines and existing U.S. brand-name drug prices that already exceed other countries' by a factor of four.